PER 4.94% 8.5¢ percheron therapeutics limited

Ann: MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK, page-13

  1. 177 Posts.
    lightbulb Created with Sketch. 46
    June 30, 2023 10:45 AM-11:45 AMCT
    In-person
    Lone Star A3 | Session Group 3a

    Join us as we discuss Duchenne Research that is Impacting Downstream. This session will repeat at 12:00pm in the Lone Star Ballroom BCapricor Therapeutics (Cap-1002) Edgewise Therapeutics (EDG-5506) FibroGen (Pamrevlumab) Antisense Therapeutics (ATL1102) Cumberland Pharmaceuticals (Ifetroban)

    Repeated:
    June 30, 2023 12:00 PM-1:00 PMCT
    In-person & virtual
    Lone Star Ballroom B | Session Group 3b
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.5¢
Change
0.004(4.94%)
Mkt cap ! $76.63M
Open High Low Value Volume
8.1¢ 8.5¢ 8.1¢ $46.54K 563.7K

Buyers (Bids)

No. Vol. Price($)
2 164616 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.5¢ 100110 1
View Market Depth
Last trade - 15.55pm 28/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.